PE20131065A1 - Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular - Google Patents

Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular

Info

Publication number
PE20131065A1
PE20131065A1 PE2013000111A PE2013000111A PE20131065A1 PE 20131065 A1 PE20131065 A1 PE 20131065A1 PE 2013000111 A PE2013000111 A PE 2013000111A PE 2013000111 A PE2013000111 A PE 2013000111A PE 20131065 A1 PE20131065 A1 PE 20131065A1
Authority
PE
Peru
Prior art keywords
distonia
kinetosis
vegetative
vascular
treatment
Prior art date
Application number
PE2013000111A
Other languages
English (en)
Spanish (es)
Inventor
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131065(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130356/15A external-priority patent/RU2542453C2/ru
Priority claimed from RU2010130353/15A external-priority patent/RU2542445C2/ru
Priority claimed from RU2011127058/15A external-priority patent/RU2536232C2/ru
Priority claimed from RU2011127052/15A external-priority patent/RU2503462C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of PE20131065A1 publication Critical patent/PE20131065A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
PE2013000111A 2010-07-21 2011-07-15 Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular PE20131065A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2010130356/15A RU2542453C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство и способ лечения вегето-сосудистой дистонии, синдрома головокружения различного генеза и кинетозов
RU2010130353/15A RU2542445C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2011127058/15A RU2536232C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2011127052/15A RU2503462C2 (ru) 2011-07-01 2011-07-01 Способ лечения головокружения различного генеза, кинетозов и вегето-сосудистой дистонии (варианты) и лекарственное средство

Publications (1)

Publication Number Publication Date
PE20131065A1 true PE20131065A1 (es) 2013-09-23

Family

ID=44899157

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000111A PE20131065A1 (es) 2010-07-21 2011-07-15 Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular

Country Status (23)

Country Link
US (1) US20130058981A1 (cg-RX-API-DMAC7.html)
EP (1) EP2596018A2 (cg-RX-API-DMAC7.html)
JP (2) JP2013536174A (cg-RX-API-DMAC7.html)
KR (1) KR20130102542A (cg-RX-API-DMAC7.html)
CN (1) CN103124741A (cg-RX-API-DMAC7.html)
AR (1) AR082314A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011281248B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013001296A2 (cg-RX-API-DMAC7.html)
CA (1) CA2805985A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013000201A1 (cg-RX-API-DMAC7.html)
DE (1) DE112011102397T5 (cg-RX-API-DMAC7.html)
EA (1) EA029998B1 (cg-RX-API-DMAC7.html)
ES (1) ES2446643R1 (cg-RX-API-DMAC7.html)
FR (1) FR2962910A1 (cg-RX-API-DMAC7.html)
GB (1) GB2496342B (cg-RX-API-DMAC7.html)
IL (1) IL224336A (cg-RX-API-DMAC7.html)
IT (1) ITTO20110630A1 (cg-RX-API-DMAC7.html)
MX (1) MX355371B (cg-RX-API-DMAC7.html)
NZ (1) NZ606988A (cg-RX-API-DMAC7.html)
PE (1) PE20131065A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013500141A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201505676RA (cg-RX-API-DMAC7.html)
WO (1) WO2012010974A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2012007845A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
ES2542042R1 (es) 2010-07-15 2015-10-06 Oleg Iliich Epshtein Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
US8637034B2 (en) 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
EP2595658A2 (en) * 2010-07-21 2013-05-29 Oleg Iliich Epshtein A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
ES2425315R1 (es) * 2010-07-21 2014-09-08 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
CN103119061A (zh) 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗注意力不足过动症的方法
GB2496801B (en) * 2010-07-21 2018-04-11 Iliich Epshtein Oleg A method of treating alzheimer's disease
JP2013537532A (ja) * 2010-08-06 2013-10-03 イリイチ・エプシテイン オレグ 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2113230C1 (ru) 1996-04-03 1998-06-20 Ильчиков Михаил Захарович Седативное лекарственное средство "авиаморе"
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
US5849528A (en) * 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US20030087250A1 (en) * 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
RU2201255C1 (ru) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
UA76638C2 (en) * 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
AU2003295328A1 (en) * 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN101107003B (zh) 2003-03-14 2012-08-08 营养学研究有限公司 用于治疗疼痛和/或炎症的顺势疗法的配剂
WO2012007845A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
ES2542042R1 (es) * 2010-07-15 2015-10-06 Oleg Iliich Epshtein Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
US8637034B2 (en) * 2010-07-15 2014-01-28 Oleg I. Epshtein Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
ES2425315R1 (es) * 2010-07-21 2014-09-08 Oleg Iliich Epshtein Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
CN103119061A (zh) * 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗注意力不足过动症的方法
EP2595658A2 (en) * 2010-07-21 2013-05-29 Oleg Iliich Epshtein A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
EP2596020A2 (en) * 2010-07-21 2013-05-29 Oleg Iliich Epshtein Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy
GB2496801B (en) * 2010-07-21 2018-04-11 Iliich Epshtein Oleg A method of treating alzheimer's disease

Also Published As

Publication number Publication date
DE112011102397T5 (de) 2013-05-08
CN103124741A (zh) 2013-05-29
CA2805985A1 (en) 2012-01-26
SG10201505676RA (en) 2015-08-28
CL2013000201A1 (es) 2015-01-23
AU2011281248A1 (en) 2013-03-14
ES2446643A2 (es) 2014-03-10
WO2012010974A8 (en) 2013-04-25
US20130058981A1 (en) 2013-03-07
NZ606988A (en) 2015-08-28
MX2013000805A (es) 2013-10-28
GB2496342A (en) 2013-05-08
SG187160A1 (en) 2013-02-28
IL224336A (en) 2017-06-29
EA029998B1 (ru) 2018-06-29
MX355371B (es) 2018-04-17
EA201300127A1 (ru) 2013-12-30
GB2496342B (en) 2017-12-06
PH12013500141A1 (en) 2013-03-11
KR20130102542A (ko) 2013-09-17
EP2596018A2 (en) 2013-05-29
ITTO20110630A1 (it) 2012-01-22
WO2012010974A3 (en) 2012-04-19
AR082314A1 (es) 2012-11-28
FR2962910A1 (fr) 2012-01-27
JP2013536174A (ja) 2013-09-19
JP2016199571A (ja) 2016-12-01
AU2011281248B2 (en) 2017-02-02
WO2012010974A2 (en) 2012-01-26
ES2446643R1 (es) 2015-03-06
BR112013001296A2 (pt) 2017-12-19
GB201302925D0 (en) 2013-04-03

Similar Documents

Publication Publication Date Title
PE20131065A1 (es) Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
PH12017500834A1 (en) Methods and formulations for treating vascular eye diseases
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
PE20140978A1 (es) Composicion farmaceutica solida que contiene amlodipina y losartan y el proceso para producirla
PH12013501636A1 (en) Treatment of osteoarthritis and pain
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
PE20151558A1 (es) Inhibidores tripeptidicos de la epoxicetona proteasa
PE20170908A1 (es) VARIANTES DE INTERFERON a2b
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
MX390739B (es) Composicion de hueso comprimido y metodo para usar la misma.
SG10201811186XA (en) Purification of proteins
MX391136B (es) FRAGMENTOS DE OspA ESTABILIZADOS CON CISTEÍNA Y MÉTODO DE USO
MX387756B (es) Composiciones de matríces extracelulares.
BR112016023498A2 (pt) composições para higiene bucal
UA107836C2 (uk) Метод лікування хвороби альцгеймера
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
MX382563B (es) Formas cristalinas de bilastina y procedimientos para su preparacion.
PE20160847A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
UA118653C2 (uk) Суперагоністи глікопротеїнового гормону тривалої дії
PE20160848A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
IN2014DN09812A (cg-RX-API-DMAC7.html)
EA201492238A1 (ru) Композиция мизопростола
EA201200028A1 (ru) Альфа-1 мультимеры hla-g и их фармацевтическое применение

Legal Events

Date Code Title Description
FC Refusal